Wellington Management Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-154,963
| Closed | -$1.54M | – | 2033 |
|
|
2025
Q2 | $1.54M | Buy |
154,963
+14,844
| +11% | +$120K | ﹤0.01% | 1635 |
|
|
2025
Q1 | $837K | Buy |
140,119
+29,787
| +27% | +$219K | ﹤0.01% | 1743 |
|
|
2024
Q4 | $847K | Buy |
110,332
+4,563
| +4% | +$39.2K | ﹤0.01% | 1747 |
|
|
2024
Q3 | $1.08M | Buy |
105,769
+18,255
| +21% | +$278K | ﹤0.01% | 1695 |
|
|
2024
Q2 | $1.3M | Buy |
87,514
+1,660
| +2% | +$23.8K | ﹤0.01% | 1607 |
|
|
2024
Q1 | $1.17M | Buy |
+85,854
| New | +$935K | ﹤0.01% | 1647 |
|
|
2023
Q2 | – | Sell |
-148,594
| Closed | -$2.02M | – | 1903 |
|
|
2023
Q1 | $2.02M | Sell |
148,594
-1,953
| -1% | -$35K | ﹤0.01% | 1511 |
|
|
2022
Q4 | $2.94M | Buy |
150,547
+28,134
| +23% | +$550K | ﹤0.01% | 1407 |
|
|
2022
Q3 | $2.33M | Buy |
122,413
+17,738
| +17% | +$409K | ﹤0.01% | 1488 |
|
|
2022
Q2 | $2.16M | Hold |
104,675
| – | – | ﹤0.01% | 1525 |
|
|
2022
Q1 | $3.37M | Sell |
104,675
-2,171
| -2% | -$78.9K | ﹤0.01% | 1489 |
|
|
2021
Q4 | $4.97M | Sell |
106,846
-116,454
| -52% | -$3.88M | ﹤0.01% | 1462 |
|
|
2021
Q3 | $6.03M | Hold |
223,300
| – | – | ﹤0.01% | 1449 |
|
|
2021
Q2 | $5.73M | Buy |
223,300
+171,700
| +333% | +$4.09M | ﹤0.01% | 1467 |
|
|
2021
Q1 | $1.76M | Sell |
51,600
-9,700
| -16% | -$351K | ﹤0.01% | 1652 |
|
|
2020
Q4 | $2.07M | Buy |
+61,300
| New | +$1.62M | ﹤0.01% | 1490 |
|
Other funds holding ITOS
Wellington Management Group's ITOS Position: Q3 2025 in Review
Wellington Management Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 154,963 shares — an estimated $1.54M sold.
Wellington Management Group first reported a position in ITOS in Q4 2020 and held it in 16 quarters. The position peaked at $6.03M in Q3 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Wellington Management Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Wellington Management Group sold 154,963 iTeos Therapeutics shares in Q3 2025, an estimated $1.54M.
- Wellington Management Group first reported a position in iTeos Therapeutics in Q4 2020 and held it in 16 quarters.
- Wellington Management Group's iTeos Therapeutics position peaked at $6.03M in Q3 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Wellington Management Group's 13F filing for Q3 2025, filed 14 Nov 2025.